Portfolio company
Mekonos
United States · £19.8m raised
Raised
£19.8m
Latest stage
Series A
Rounds recorded
1
Backed by
1 investor
Sectors
About
The company develops a silicon-based system-on-a-chip platform for automated ex vivo delivery of molecular cargo into individual cells for cell and gene therapy developers.
SourceFunding history · 1
Similar companies
Kytopen
This company develops non-viral gene delivery platforms for biotechnology researchers and pharmaceutical manufacturers to accelerate the production of gene-modified cell therapies.
Indee Labs
Indee Labs develops microfluidic cell engineering instruments for pharmaceutical and biotechnology companies to deliver gene-editing materials into immune cells for therapeutic development.
Basilard Biotech
Basilard Biotech develops gene delivery technology for cell and gene therapy manufacturers to facilitate nanomechanical engineering of cell-based treatments.
CellFE
The company develops microfluidic platforms for intracellular delivery of molecules to support cell therapy developers and researchers in manufacturing engineered cells.
MFX
This company develops automated microfluidic bioreactor platforms and data generation infrastructure for researchers and manufacturers in the cell and gene therapy sector.
Spot Biosystems
This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.
Gene Therapy Delivery Methods
This company develops viral and non-viral vector platforms to provide genetic material delivery solutions for biotechnology firms and healthcare providers.
Transforming cells into cures
This company develops a cellular engineering platform to design and optimize cell therapies for biopharmaceutical developers and research institutions.
